Cargando…

Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study

PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Bo, Cheng, Huihui, Li, Kunhong, Lv, Yukai, Zeng, Xianshang, Liu, Tao, Yu, Weiguang, Guo, Wenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508031/
https://www.ncbi.nlm.nih.gov/pubmed/34973080
http://dx.doi.org/10.1007/s00432-021-03873-3
_version_ 1784796931207200768
author Xu, Bo
Cheng, Huihui
Li, Kunhong
Lv, Yukai
Zeng, Xianshang
Liu, Tao
Yu, Weiguang
Guo, Wenbo
author_facet Xu, Bo
Cheng, Huihui
Li, Kunhong
Lv, Yukai
Zeng, Xianshang
Liu, Tao
Yu, Weiguang
Guo, Wenbo
author_sort Xu, Bo
collection PubMed
description PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46–75]; CN: n = 64, 63 years [47–72]). The median duration of follow-up was 27 months [range 1–37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3–22.5) in the ACN group vs. 14.8 months (95% CI 12.5–17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33–0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7–9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6–6.8; HR 0.60; 95% CI 0.38–0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile.
format Online
Article
Text
id pubmed-9508031
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-95080312022-09-25 Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study Xu, Bo Cheng, Huihui Li, Kunhong Lv, Yukai Zeng, Xianshang Liu, Tao Yu, Weiguang Guo, Wenbo J Cancer Res Clin Oncol Original Article – Clinical Oncology PURPOSE: The aim of this retrospective review was to compare the efficacy and safety of the atezolizumab plus carboplatin and nab-paclitaxel regimen versus the carboplatin and nab-paclitaxel regimen as front-line management for treatment-naïve, metastatic nonsquamous programmed death-ligand 1 (PD-L1)-positive non-small cell lung cancer (NSCLC) in a selected population. METHODS: Consecutive patients with untreated, metastatic nonsquamous PD-L1-positive NSCLC who initially received the atezolizumab plus carboplatin and nab-paclitaxel (ACN) regimen or carboplatin and nab-paclitaxel (CN) regimen were retrospectively identified in two medical institutions from 2017 to 2020. The co-primary end points were overall survival (OS) and progression-free survival (PFS); secondary end point was the rate of key adverse events (AEs). RESULTS: In sum, 171 patients were retrospectively analysed, 47 of whom were excluded according to the criteria used in this study, leaving 124 patients (ACN: n = 60, median age 64 years [range 46–75]; CN: n = 64, 63 years [47–72]). The median duration of follow-up was 27 months [range 1–37]. At the final follow-up, the median OS was 19.9 months (95% confidence interval [CI], 16.3–22.5) in the ACN group vs. 14.8 months (95% CI 12.5–17.2) in the CN group (hazard ratio [HR] 0.51, 95% CI 0.33–0.77; p = 0.001). A marked distinction in the median PFS was seen (8.5 months [95% CI 6.7–9.4] in the ACN group vs. in the CN group [5.1 months [95% CI 3.6–6.8; HR 0.60; 95% CI 0.38–0.95; p = 0.005]). The rates of the key AEs (neutropenia and anaemia) were greater in the ACN group than in the CN group (all p < 0.05), but these AEs were manageable. CONCLUSION: Among selected populations of individuals with treatment-naïve, metastatic nonsquamous PD-L1-positive NSCLC, atezolizumab combined with carboplatin and nab-paclitaxel chemotherapy might have encouraging anticancer activity, with a tolerable safety profile. Springer Berlin Heidelberg 2022-01-01 2022 /pmc/articles/PMC9508031/ /pubmed/34973080 http://dx.doi.org/10.1007/s00432-021-03873-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article – Clinical Oncology
Xu, Bo
Cheng, Huihui
Li, Kunhong
Lv, Yukai
Zeng, Xianshang
Liu, Tao
Yu, Weiguang
Guo, Wenbo
Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
title Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
title_full Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
title_fullStr Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
title_full_unstemmed Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
title_short Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study
title_sort carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naïve metastatic nonsquamous non-small cell lung cancer with pd-l1 staining: a retrospective study
topic Original Article – Clinical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508031/
https://www.ncbi.nlm.nih.gov/pubmed/34973080
http://dx.doi.org/10.1007/s00432-021-03873-3
work_keys_str_mv AT xubo carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT chenghuihui carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT likunhong carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT lvyukai carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT zengxianshang carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT liutao carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT yuweiguang carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy
AT guowenbo carboplatinandnabpaclitaxelchemotherapywithorwithoutatezolizumabasfrontlinemanagementfortreatmentnaivemetastaticnonsquamousnonsmallcelllungcancerwithpdl1stainingaretrospectivestudy